Tigecycline and overall mortality

Clinical Infectious Diseases

Volumn 55, Issue 12, 2012, Pages 1739-

  Yahav, Dafna ^a,b   Lador, Adi ^a,b   Paul, Mical ^a,b   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ATTRIBUTABLE RISK; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION RISK; LETTER; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT;

ANTI-BACTERIAL AGENTS; HUMANS; MINOCYCLINE;

EID: 84870175965     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis759     Document Type: Letter

References (4)

1. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: A systematic review and meta-Analysis. J Antimicrob Chemother 2011; 66:1963-71.
2. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-Analysis. Lancet Infect Dis 2011; 11:834-44.
3. Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis 2012; 54:1699-709.
4. Qvist N, Warren B, Leister-Tebbe H, et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-Abdominal infections: Results from a randomized, controlled trial. Surg Infect (Larchmt) 2012; 13:102-9.